Despite Slowdown Fears, No Change in China IVD Forecast

Despite Slowdown Fears, No Change in China IVD Forecast

Make sure to visit our In Vitro Diagnostics page, Kalorama's all-in-one resource covering the IVD market.

Despite concern over a slowing Chinese economy, Kalorama Information does not see a lower estimate for the IVD industry.  A few months ago we estimated that in 2014, the China IVD market was $2.2 billion and is expected to show annual growth of 14.1% to reach $4.2 billion in 2019.  We still see that estimate as most likely.   The breakneck expansion of the past has tempered - a large population in need of healthcare will continue spur Chinese market growth.

Supporting China IVD market growth will be a modernizing healthcare infrastructure and steady migration from manual to automated processes. China is the world's largest country with a population of over 1 billion, and is the world's single largest potential market for goods and services.  China is Southeast Asia's largest land mass and is also culturally diverse as it borders on a large number of ethically distinct areas. The country’s largest metropolitan areas, including Beijing, Shanghai, Shenyang, Harbin and Guangzhou, are found on its East coast, and account for almost half of its population.

The China IVD market trails only the populous, developed markets of the United States, western European countries, and Japan. China represents the second largest clinical laboratory market in the Asia-Pacific, following only Japan, and the fastest growing among the top ten in vitro diagnostics markets.  

China will continue to offer one of the fastest growing markets for IVD products, even for western-style lab instrumentation and advanced tests outside of recent public healthcare network expansion. Leading IVD companies have established themselves in China and are seeking long-term market growth, with significant investments necessary to gain China IVD market share and develop products for the domestic market and for international distribution. Kalorama expects a gradual decline through 2019 as facilities obtain needed  equipment and upgrades become less frequent. This will result in a declining compound annual growth rate (CAGR) from 14.1% in the 2014 to 2019 period to 13.2% in the 2019 to 2024 period.  

Product opportunities for international IVD companies in the Chinese market include  easy-to-use rapid tests with built-in high specificity and sensitivity for applications in rural healthcare; instrumentation in advanced diagnostics, including sequencers and molecular test analyzers; microarrays and other multi-analyte molecular assays; and multi-tool analyzers capable of running hematology and immunodiagnostic assays. Our report, IVD in China Market Outlook 2014-2024, presents current analysis of the Chinese IVD industry and provides forecasts to 2024. The report takes an in-depth look at the China IVD market, providing data on total Chinese market size and growth, as well as on the following China IVD market segments: Immunoassays, Clinical Chemistry, Hematology, Point of Care, Molecular Testing, Urinalysis, and other tests. The report can be found at: